Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements - Narrative (Details)

v3.20.4
Fair Value Measurements - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 03, 2020
USD ($)
agreement
Nov. 01, 2019
USD ($)
$ / shares
shares
Apr. 30, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Mar. 31, 2020
USD ($)
agreement
Dec. 31, 2020
USD ($)
class_of_stock
Dec. 31, 2019
USD ($)
class_of_stock
$ / shares
Dec. 31, 2018
USD ($)
Level 3 Valuation                
Investment in Aytu       $ 0   $ 0 $ 7,628,947  
Net proceeds     $ 12,800,000     44,400,000   $ 5,700,000
Realized gain           5,200,000    
Change in fair value of contingent consideration           0 $ 1,256,211  
Additions           $ 900,000    
Useful life           10 months 24 days 1 year 10 months 24 days  
Number of changes in valuation techniques | class_of_stock           0 0  
Amount of transfers of assets from level 2 to level 1       0   $ 0 $ 0  
Amount of transfers of assets from level 1 to level 2       0   0 0  
Level 3 | Contingent Consideration                
Level 3 Valuation                
Contingent consideration       $ 0   0 0 $ 1,300,000
Change in fair value of contingent consideration           $ 0 1,300,000  
Common stock                
Level 3 Valuation                
Net proceeds     $ 12,800,000          
Pediatric Portfolio | Convertible Preferred Stock                
Level 3 Valuation                
Shares received as consideration (in shares) | shares   9,805,845 9,805,845 9,805,845        
Shares received as consideration, price per share (in dollars per share) | $ / shares   $ 1.2747            
AYTU | Convertible Preferred Stock | Level 2                
Level 3 Valuation                
Investment in Aytu   $ 7,600,000         $ 7,600,000  
AYTU | Convertible Preferred Stock | Level 2 | Measurement input share price (in dollars per share)                
Level 3 Valuation                
Share price (in dollars per share) | $ / shares   $ 1.03         $ 0.9725  
AYTU | Convertible Preferred Stock | Level 2 | Measurement input, discount for lack of marketability                
Level 3 Valuation                
Equity securities, measurement input   0.25         0.20  
Aevi                
Level 3 Valuation                
Extended employment agreements | agreement 7       7      
Useful life         2 years      
Acquired Assembled Workforce                
Level 3 Valuation                
Useful life           1 year 1 month 6 days 9 months 18 days  
Acquired Assembled Workforce | Aevi                
Level 3 Valuation                
Additions $ 900,000       $ 900,000      
Useful life 2 years         2 years